PDF herunterladen
Krankenhaushygiene up2date 2007; 2(1): 21-36
DOI: 10.1055/s-2007-966252
Antibiotikaanwendung

© Georg Thieme Verlag KG Stuttgart · New York

Antibiotikaanwendung und Resistenzentwicklung

Bernd  Wiedemann
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
02. April 2007 (online)

Auch verfügbar auf
    Lizenzen und Reprints Alle Artikel dieser Rubrik

Kernaussagen

Durch die Zunahme multimorbider Patienten, die in hohem Maße für komplizierte Infektionen mit multiresistenten Bakterien prädisponiert sind, ist es notwendig, klare Strategien zur Eindämmung der Resistenzentwicklung anzuwenden. Dazu gehört in erster Linie ein mikrobiologisches Laboratorium mit modernen Methoden zur Identifizierung von Mikroorganismen und zu deren Resistenzbestimmung auf hohem methodischem Niveau (Bestimmung der MHK) mit hinreichender, auch klinisch-infektiologischer Sachkenntnis. Eine Auswertung aller mikrobiologischer Befunde mit der entsprechenden Aufbereitung zu übersichtlichen Statistiken, ein enger Kontakt zwischen Labor und behandelndem Arzt, eine effektive Antibiotikakontrolle, die sich an den spezifischen mikrobiologischen Daten orientiert und konsequent durchgehalten werden muss und eine ständige Infektionskontrolle sind unabdingbare Voraussetzungen. Alle an diesem Programm beteiligten Personen müssen dabei eng und vertrauensvoll zusammenarbeiten.

Literatur

  • 1 Drosten C, Gunther S, Preiser W. et al . Identification of a novel coronavirus in patients with severe acute respiratory syndrome.  N Engl J Med. 2003;  348 1967-1976
    CrossrefPubMedGoogle Scholar
  • 2 Livermore D M. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?.  Clin Infect Dis. 2002;  34 634-640
    CrossrefGoogle Scholar
  • 3 Urban C, Segal-Maurer S, Rahal J J. Considerations in control and treatment of nosocomial infections due to multidrug-resistant Acinetobacter baumannii.  Clin Infect Dis. 2003;  36 1268-1274
    CrossrefGoogle Scholar
  • 4 Vandenesch F, Naimi T, Enright M C. et al . Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence.  Emerg Infect Dis. 2003;  9 978-984
    CrossrefPubMedGoogle Scholar
  • 5 Peterson L R. Squeezing the antibiotic balloon: the impact of antimicrobial classes on emerging resistance.  Clin Microbiol Infect. 2005;  11 Suppl 5 4-16
    CrossrefGoogle Scholar
  • 6 Austin D J, Kristinsson K G, Anderson R M. The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance.  Proc Natl Acad Sci USA. 1999;  96 1152-1156
    CrossrefGoogle Scholar
  • 7 Bronzwaer S L, Cars O, Buchholz U. et al . A European study on the relationship between antimicrobial use and antimicrobial resistance.  Emerg Infect Dis. 2002;  8 278-282
    CrossrefGoogle Scholar
  • 8 Garcia-Rey C, Martin-Herrero JE, Baquero F. Antibiotic consumption and generation of resistance in Streptococcus pneumoniae: the paradoxical impact of quinolones in a complex selective landscape.  Clin Microbiol Infect. 2006;  12 Suppl 3 55-66
    Google Scholar
  • 9 Barger A, Fuhst C, Wiedemann B. Pharmacological indices in antibiotic therapy.  J Antimicrob Chemother. 2003;  52 893-898
    CrossrefGoogle Scholar
  • 10 Stock I, Wiedemann B. Natural antibiotic susceptibility of Klebsiella pneumoniae, K. oxytoca, K. planticola, K. ornithinolytica and K. terrigena strains.  J Med Microbiol. 2001;  50 396-406
    Google Scholar
  • 11 Heisig P, Wiedemann B. [Action and reaction. Actions and resistance mechanisms of quinolone].  PharmUnserer Zeit. 2001;  30 382-393
    Google Scholar
  • 12 Firsov A A, Sirnova M V, Lubenko I Y. et al . Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model.  J Antimicrob Chemother. 2006;  58 1185-1192
    CrossrefGoogle Scholar
  • 13 Hawkey P M. Quinolones in sweat and quinolone resistance.  Lancet. 1997;  349 148-149
    CrossrefGoogle Scholar
  • 14 Kresken M, Hafner D. Drug resistance among clinical isolates of frequently encountered bacterial species in central Europe during 1975 - 1995. Study Group Bacterial Resistance of the Paul-Ehrlich-Society for Chemotherapy.  Infection 27 Suppl. 1999;  2 2-8
    Google Scholar
  • 15 Harbarth S, Liassine N, Dharan S. et al . Risk factors for persistent carriage of methicillin-resistant Staphylococcus aureus.  Clin Infect Dis. 2000;  31 1380-1385
    CrossrefGoogle Scholar
  • 16 Vakulenko S B, Mobashery S. Versatility of aminoglycosides and prospects for their future.  Clin Microbiol Rev. 2003;  16 430-450
    CrossrefPubMedGoogle Scholar
  • 17 Gerding D N, Larson T A, Hughes R A. et al . Aminoglycoside resistance and aminoglycoside usage: ten years of experience in one hospital.  Antimicrob Agents Chemother. 1991;  35 1284-1290
    Google Scholar
  • 18 VanLanduyt H W, Boelaert J, Glibert B, Gordts B, Verbruggen A M. Surveillance of aminoglycoside resistance. European data.  Am J Med. 1986;  80 76-81
    Google Scholar
  • 19 Livermore D. Bacterial resistance to carbapenems.  Adv Exp Med Biol. 1995;  390 25-47
    Google Scholar
  • 20 Burke J P. Antibiotic resistance-squeezing the balloon?.  JAMA. 1998;  280 1270-1271
    CrossrefGoogle Scholar
  • 21 Rahal J J, Urban C, Horn D. et al . Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella.  JAMA. 1998;  280 1233-1237
    Google Scholar
  • 22 Livermore D M. The impact of carbapenemases on antimicrobial development and therapy.  Curr Opin Investig Drugs. 2002;  3 218-224
    Google Scholar
  • 23 Wiegand I, Wiedemann B. Microbial Resistance to Drugs. In: Offermanns S,Rosenthal W (eds) Encyclopedic Reference of Molecular Pharmacology. Berlin, Heidelberg; Springer 2004: 594-600
    Google Scholar
  • 24 Eveillard M, Schmit J L, Eb F. Antimicrobial use prior to the acquisition of multiresistant bacteria.  Infect Control Hosp Epidemiol. 2002;  23 155-158
    CrossrefGoogle Scholar
  • 25 Lee S O, Kim N J, Choi S H. et al . Risk factors for acquisition of imipenem-resistant Acinetobacter baumannii: a case-control study.  Antimicrob Agents Chemother. 2004;  48 224-228
    CrossrefGoogle Scholar
  • 26 Carmeli Y, Eliopoulos G M, Samore M H. Antecedent treatment with different antibiotic agents as a risk factor for vancomycin-resistant Enterococcus.  Emerg Infect Dis. 2002;  8 802-807
    Google Scholar
  • 27 Tokars J I, Satake S, Rimland D. et al . The prevalence of colonization with vancomycin-resistant Enterococcus at a Veterans’ Affairs institution.  Infect Control Hosp Epidemiol. 1999;  20 171-175
    CrossrefGoogle Scholar
  • 28 Anand A, Bashey B, Mir T, Glatt A E. Epidemiology, clinical manifestations, and outcome of Clostridium difficile-associated diarrhea.  Am J Gastroenterol. 1994;  89 519-523
    Google Scholar
  • 29 Carling P, Fung T, Killion A, Terrin N, Barza M. Favorable impact of a multidisciplinary antibiotic management program conducted during 7 years.  Infect Control Hosp Epidemiol. 2003;  24 699-706
    CrossrefGoogle Scholar
  • 30 Yip C, Loeb M, Salama S, Moss L, Olde J. Quinolone use as a risk factor for nosocomial Clostridium difficile-associated diarrhea.  Infect,Control Hosp Epidemiol. 2001;  22 572-575
    Google Scholar
  • 31 Bush K. New beta-lactamases in gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy.  Clin Infect Dis. 2001;  32 1085-1089
    CrossrefGoogle Scholar
  • 32 Nordmann P. Trends in beta-lactam resistance among Enterobacteriaceae.  Clin Infect Dis 27 Suppl. 1998;  1 100-106
    Google Scholar
  • 33 Fasola E L, Fasching C E, Peterson L R. Molecular correlation between in vitro and in vivo activity of beta-lactam and beta-lactamase inhibitor combinations against methicillin-resistant Staphylococcus aureus.  J Lab Clin Med. 1995;  125 200-211
    Google Scholar
  • 34 Yokota T. Inactivation of beta-lactamases by sulbactam and enhanced clinical activity due to target-site binding of the combination of sulbactam and ampicillin.  APMIS Suppl. 1989;  5 9-16
    Google Scholar
  • 35 Finlay J, Miller L, Poupard J A. A review of the antimicrobial activity of clavulanate.  J Antimicrob Chemother. 2003;  52 18-23
    CrossrefGoogle Scholar
  • 36 Hawkey P M. Mechanisms of quinolone action and microbial response.  J Antimicrob Chemother 51 Suppl. 200;  1 29-35
    Google Scholar
  • 37 Hooper D C. Mechanisms of action of antimicrobials: focus on fluoroquinolones.  Clin Infect Dis 32 Suppl. 2001;  1 9-15
    Google Scholar
  • 38 Neuhauser M M, Weinstein R A, Rydman R. et al . Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use.  JAMA. 2003;  289 885-888
    CrossrefGoogle Scholar
  • 39 Kaye K S, Kanafani Z A, Dodds A E. et al . Differential effects of levofloxacin and ciprofloxacin on the risk for isolation of quinolone-resistant Pseudomonas aeruginosa.  Antimicrob Agents Chemother. 2006;  50 2192-2196
    CrossrefGoogle Scholar
  • 40 Li X Z, Nikaido H. Efflux-mediated drug resistance in bacteria.  Drugs. 2004;  64 159-204
    CrossrefGoogle Scholar
  • 41 Oh H, Stenhoff J, Jalal S, Wretlind B. Role of efflux pumps and mutations in genes for topoisomerases II and IV in fluoroquinolone-resistant Pseudomonas aeruginosa strains.  Microb Drug Resist. 2003;  9 323-328
    CrossrefGoogle Scholar
  • 42 Freeman C D, Nicolau D P, Belliveau P P, Nightingale C H. Once-daily dosing of aminoglycosides: review and recommendations for clinical practice.  J Antimicrob Chemother. 1997;  39 677-686
    CrossrefGoogle Scholar
  • 43 Gilbert D N. Once-daily aminoglycoside therapy.  Antimicrob Agents Chemother. 1991;  35 399-405
    Google Scholar
  • 44 Karlowsky J A, Jones M E, Thornsberry C, Friedland I R, Sahm D F. Trends in antimicrobial susceptibilities among Enterobacteriaceae isolated from hospitalized patients in the United States from 1998 to 2001.  Antimicrob Agents Chemother. 2003;  47 1672-1680
    CrossrefGoogle Scholar
  • 45 Zervos M J, Hershberger E, Nicolau D P. et al . Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991 - 2000.  Clin Infect Dis. 2003;  37 1643-1648
    CrossrefGoogle Scholar
  • 46 Peterson L R, Postelnick M, Pozdol T L, Reisberg B, Noskin G A. Management of fluoroquinolone resistance in Pseudomonas aeruginosa - outcome of monitored use in a referral hospital.  Int J Antimicrob Agents. 1998;  10 207-214
    Google Scholar
  • 47 Paladino J A, Sunderlin J L, Forrest A, Schentag J J. Characterization of the onset and consequences of pneumonia due to fluoroquinolone-susceptible or -resistant Pseudomonas aeruginosa.  J Antimicrob Chemother. 2003;  52 457-463
    Google Scholar
  • 48 Beyer R, Pestova E, Millichap J J. et al . A convenient assay for estimating the possible involvement of efflux of fluoroquinolones by Streptococcus pneumoniae and Staphylococcus aureus: evidence for diminished moxifloxacin, sparfloxacin, and trovafloxacin efflux.  Antimicrob Agents Chemother. 2000;  44 798-801
    Google Scholar
  • 49 Davidson R J, Campbell S. Increased use of the 8-methoxy-fluoroquinolones correlates with a decrease in fluoroquinolone resistance among Streptococcus pneumoniae in the maritime region of Canada. San Francisco; ICAAC 2006: Abstract C2-434
    Google Scholar
  • 50 Graffunder E M, Venezia R A. Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials.  J Antimicrob Chemother. 2002;  49 999-1005
    CrossrefGoogle Scholar
  • 51 Weber S G, Gold H S, Hooper D C, Karchmer A W, Carmeli Y. Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients.  Emerg Infect Dis. 2003;  9 1415-1422
    CrossrefGoogle Scholar
  • 52 Gaynes R, Rimland D, Killum E. et al . Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use.  Clin Infect Dis. 2004;  38 640-645
    CrossrefGoogle Scholar
  • 53 McCusker M E, Harris A D, Perencevich E, Roghmann M C. Fluoroquinolone use and Clostridium difficile-associated diarrhea.  Emerg Infect Dis. 2003;  9 730-733
    Google Scholar
  • 54 Gerding D N. Clindamycin, cephalosporins, fluoroquinolones, and Clostridium difficile-associated diarrhea: this is an antimicrobial resistance problem.  Clin Infect Dis. 2004;  38 646-648
    CrossrefGoogle Scholar
  • 55 Bradley S J, Kaufmann M E, Happy C. et al . The epidemiology of glycopeptide-resistant enterococci on a haematology unit-analysis by pulsed-field gel electrophoresis.  Epidemiol Infect. 2002;  129 57-64
    CrossrefGoogle Scholar
  • 56 Wilhelm M P, Estes L. Symposium on antimicrobial agents-Part XII. Vancomycin.  Mayo Clin Proc. 1999;  74 928-935
    Google Scholar
  • 57 Hiramatsu K. The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan.  Am J Med. 1998;  104 7-10
    CrossrefGoogle Scholar
  • 58 Bozdogan B, Appelbaum P C. Oxazolidinones: activity, mode of action, and mechanism of resistance.  Int J Antimicrob Agents. 2004;  23 113-119
    CrossrefPubMedGoogle Scholar
  • 59 Wiedemann B. Test results: characterising the antimicrobial activity of daptomycin.  Clin Microbiol Infect. 2006;  8 Suppl 12 9-14
    Google Scholar
  • 60 Allington D R, Rivey M P. Quinupristin/dalfopristin: a therapeutic review.  Clin Ther. 2001;  23 24-44
    CrossrefGoogle Scholar
  • 61 Karakitsos D, Paramythiotou E, Samonis G, Karabinis A. Is intraventricular colistin an effective and safe treatment for post-surgical ventriculitis in the intensive care unit?.  Acta Anaesthesiol Scand. 2006;  50 1309-1310
    CrossrefGoogle Scholar
  • 62 Jones C H, Petersen P J. Tigecycline: a review of preclinical and clinical studies of the first-in-class glycylcycline antibiotic.  Drugs Today (Barc). 2005;  41 637-659
    CrossrefGoogle Scholar

Prof. Dr. Bernd Wiedemann

Böstens Hoi 15
24882 Schaalby

eMail: be-wiedemann@t-online.de